INVO Fertility, Inc IVF

INVO Fertility, Inc. will participate in the Lytham Partners Fall 2026 Investor Conference via webcast on Sept. 29, 2026 at 11:30 a.m. ET, with virtual one-on-one meetings with investors to follow. Management will present and meet with attendees; contact Lytham Partners to arrange meetings. INVO Fertility is a healthcare services fertility company focused on building, acquiring, and operating U.S. fertility clinics and related technologies, including INVOcell. The company currently operates four clinics and sells INVOcell to third-party clinics. The conference aims to bolster investor visibility and communication, with no immediate business changes announced. Increased investor visibility and sentiment from conference participation, with limited near-term impact on fundamentals or operations.

INVO Fertility Inc reported 17% revenue growth in Q2 2026 earnings highlights driven by stronger clinic-level results. 17% revenue increase signals moderate improvement in financial performance without indicating transformative shifts.

INVO Fertility reported a 17% rise in Q2 revenue with improved profitability at the clinic level. Positive Q2 revenue growth and clinic profitability gains point to better operational results that can moderately influence financial performance and investor views.

INVO Fertility reported second quarter 2026 results with revenue growth and profitability achieved in its clinic platform. Revenue growth and clinic profitability signal operational progress that may lift near-term valuation without reshaping long-term strategy.

INVO Fertility reported first quarter 2026 results with strong revenue growth, expanded fertility clinic platform, and improved capital structure. Revenue growth plus platform expansion and capital improvements signal major positive shifts in operations and outlook.

INVO Fertility, Inc. released its fiscal year 2025 financial results. Annual financial results release supplies performance data that can shift near-term investor views and valuation.

INVO Fertility, Inc. (IVF) received a Nasdaq notification for the late filing of its Annual Report on Form 10-K. Nasdaq notice for late 10-K filing signals compliance issues that could pressure stock price and investor confidence in the short term.

INVO Fertility, Inc. (IVF) announced a 1:5 reverse stock split effective pre-market opening on March 27, 2026. Reverse stock split consolidates shares to boost nominal price for listing compliance but typically signals financial weakness and harms long-term sentiment.

INVO Fertility announces availability of advanced incubation technology at its Wisconsin clinic. Rollout of advanced incubation technology at a key clinic bolsters operational efficiency and competitive positioning in fertility services.

INVO Fertility's Wisconsin clinic joined the Progyny Network, expanding access to INVO's INVOcell technology for Progyny's employer-sponsored fertility benefit members. Joining Progyny's network provides INVO Fertility significant new patient referrals and revenue potential through a leading fertility benefits provider.

INVO Fertility, Inc. (IVF) closed its acquisition of Indiana-based fertility clinic Family Beginnings, expanding its network of clinics and enhancing service offerings in the Midwest. Acquisition bolsters INVO Fertility's physical presence and revenue streams through clinic expansion in a key market.

INVO Fertility, Inc. has received a patent for its modified INVOcell® device, which is designed to enhance the in vitro fertilization process. This innovation aims to improve embryo development and increase success rates for patients undergoing fertility treatments. The patent issuance is expected to strengthen INVO Fertility's position in the reproductive health market and may lead to further advancements in their product offerings. The patent issuance for the modified INVOcell® device is likely to significantly enhance product offerings and competitive positioning in the fertility market.

INVO Fertility, Inc. has issued a shareholder letter emphasizing its strengthened fundamental position and outlining a strategic outlook for growth. The letter highlights key developments and initiatives aimed at enhancing the company's market presence and operational efficiency, signaling a commitment to long-term success in the fertility industry. The strategic outlook and initiatives presented are likely to significantly impact the company's future performance and investor sentiment.

INVO Fertility, Inc. has entered into a $7.5 million warrant inducement priced at-the-market under Nasdaq rules. This move is aimed at attracting investors and enhancing the company's financial position. The warrants are expected to provide additional capital for future growth initiatives. The warrant inducement is likely to provide moderate financial support, influencing the company's operations and market sentiment.

INVO Fertility, Inc. has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. This surge in activity may reflect broader trends in the fertility industry or specific developments within the company that are attracting attention from traders and investors alike. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

INVO Fertility, Inc (IVF) has seen a remarkable 215% increase in stock price over the past five days, drawing attention to its recent penny stock rally. Investors are questioning whether this surge is sustainable or if it represents a speculative bubble. The company operates in the fertility sector, which has been gaining traction, but the volatility of penny stocks raises concerns about the long-term viability of such rapid price changes. The significant stock price increase indicates heightened market interest, but the inherent volatility of penny stocks limits the overall impact on long-term performance.

INVO Fertility, Inc. (IVF) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. This surge in activity may reflect broader trends in the fertility industry or specific developments within the company that have captured attention. Investors are closely monitoring IVF's performance as it navigates market dynamics and potential growth opportunities. Increased trading activity suggests moderate investor interest, which may influence market sentiment and financial performance.

INVO Fertility, Inc. will participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026. This event is expected to provide a platform for the company to engage with investors and discuss its strategic initiatives and growth prospects in the fertility sector. Participation in investor summits can enhance visibility and investor relations, potentially influencing market sentiment and financial performance.

INVO Fertility, Inc. has restructured its executive leadership to align with its growth strategy, aiming to enhance operational efficiency and support future expansion. The changes are part of a broader initiative to strengthen the company's market position and drive innovation in fertility services. The leadership restructuring is a significant strategic move that could enhance operational efficiency and market positioning.

INVO Fertility, Inc. has signed a definitive purchase agreement to acquire Family Beginnings, a fertility clinic based in Indiana. This acquisition is part of INVO's strategy to expand its footprint in the fertility services market and enhance its offerings to patients. The deal is expected to strengthen INVO's position in the industry and provide additional resources for growth. The acquisition of Family Beginnings is a significant strategic move that could enhance INVO's market position and operational capabilities.

INVO Fertility, Inc. has announced its intention to acquire Family Beginnings, a fertility clinic based in Indiana. This strategic move aims to expand INVO's footprint in the fertility services market and enhance its offerings to patients. The acquisition is expected to bolster INVO's operational capabilities and strengthen its position in the competitive landscape of reproductive health. The acquisition of Family Beginnings is a significant strategic move that could enhance INVO's market position and operational capabilities.

INVO Fertility, Inc. announced a 1:8 reverse stock split effective before the market opens on November 28, 2025. This move is aimed at increasing the company's stock price and improving its market position. The reverse stock split may influence market sentiment and financial performance but is not expected to fundamentally alter the company's trajectory.

INVO Fertility, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational developments. The company continues to focus on expanding its services and improving patient outcomes in the fertility sector. Management expressed optimism about future growth prospects and strategic initiatives aimed at enhancing market position. Revenue growth and operational developments indicate a moderately noticeable influence on financial performance and market positioning.

INVO Fertility, Inc. has partnered with Heidi Health to integrate AI-powered tools into its Wisconsin Fertility Institute. This collaboration aims to enhance patient care and streamline fertility treatment processes through advanced technology, potentially improving outcomes for patients seeking fertility assistance. The partnership with Heidi Health is a significant strategic move that could enhance INVO's service offerings and competitive positioning in the fertility market.

INVO Fertility, Inc. reported its earnings for the second quarter of 2025, highlighting key financial metrics and operational developments. The company showed growth in revenue and patient volume, driven by increased demand for its fertility services. Management provided insights into future strategies and market positioning, emphasizing ongoing investments in technology and service expansion. The report reflects a positive outlook for the company amid a competitive landscape in the fertility industry. The earnings report indicates significant growth and strategic initiatives that could alter the company's trajectory and investor sentiment.

INVO Fertility, Inc. reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue growth and operational achievements. The company continues to expand its services and improve patient outcomes, reflecting a positive trend in its business model. Management expressed optimism about future growth prospects and strategic initiatives aimed at enhancing market presence. Revenue growth and operational achievements indicate a moderately noticeable influence on financial performance and market positioning.

INVO Fertility, Inc. has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. This surge in activity may reflect broader trends in the fertility industry or specific developments within the company that have caught the attention of traders and analysts alike. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

INVO Fertility, Inc. announced a 1-for-3 reverse stock split effective July 21, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share. Post-split, the company will have approximately 928,272 shares outstanding and 1,388,888 authorized shares. The common stock will continue to trade under the symbol 'IVF'. The reverse stock split aims to meet Nasdaq listing requirements, which could moderately influence market perception and compliance.

INVO Fertility, Inc. announced enhancements to its INVOcell technology, including expanded training for clinicians and improved pricing to increase accessibility. INVOcell, the first FDA-cleared intravaginal culture system, allows fertilization and early embryo development within the woman's body, offering a more natural alternative to traditional IVF with comparable success rates. The company aims to boost market awareness through educational campaigns and continues to focus on expanding its fertility clinic operations. The enhancements to INVOcell technology and the strategic focus on expanding clinic operations are likely to significantly impact the company's market position and investor sentiment.

INVO Fertility, Inc. has introduced Platelet-Rich Plasma (PRP) therapy at its Wisconsin Fertility Institute center, enhancing its fertility services. PRP therapy utilizes the body's growth factors to promote uterine lining growth and ovarian rejuvenation, potentially improving implantation rates. It is particularly beneficial for women with specific fertility challenges, offering a minimally invasive alternative before considering egg donation or surrogacy. CEO Steve Shum emphasized the therapy's potential to provide new options for patients, while Dr. Gretchen Collins noted its experimental yet promising nature in reproductive medicine. Interested patients can schedule consultations through the institute's website or phone. The introduction of PRP therapy represents a significant enhancement to INVO Fertility's service offerings, potentially attracting more patients and improving financial performance.